ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,321.495
-0.49%
Brent Oil
81.97
-0.19%
Bitcoin
66,510.01
-0.19%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTA)

  7. Pasithea Therapeutics Corporation (KTTA) News

Pasithea Therapeutics (KTTA)

Pasithea Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KTTA
DateTimeSourceHeadlineSymbolCompany
13/06/202411:59GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialNASDAQ:KTTAPasithea Therapeutics Corporation
28/05/202411:59GlobeNewswire Inc.Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
29/04/202412:59GlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
24/04/202412:59GlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202402:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
13/02/202412:59GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
18/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
08/01/202412:59GlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAPasithea Therapeutics Corporation
02/01/202421:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
02/01/202413:35GlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202322:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202322:00GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202316:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
19/12/202322:26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
19/12/202322:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
19/12/202322:19GlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
11/12/202313:01GlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202322:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202321:27GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202312:59GlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAPasithea Therapeutics Corporation
13/11/202321:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTTAPasithea Therapeutics Corporation
09/11/202312:59GlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202322:01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAPasithea Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:KTTA

Your Recent History

LSE
GKP
Gulf Keystone Petroleum
LSE
LLOY
Lloyds Banking
LSE
SVE
Starvest
LSE
CPL
LSE
TW.
Taylor Wimpey
LSE
HZM
Horizonte Minerals
LSE
RBD
Reabold Resources
LSE
PANR
Pantheon Resources
LSE
KMK
Kromek
LSE
IQG
Iqgeo
LSE
HE1
Helium One Global
LSE
SQZ
Serica Energy
LSE
XPF
Xp Factory
LSE
ESO
Epe Special Opportunities
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved